“Jim and Brian bring broad experience and creative ideas to Second Genome’s leadership team as we continue to grow our microbiome profiling platform to tackle new challenges, as well as expand our pipeline programs,” said Glenn Nedwin, Chief Executive Officer and President of Second Genome.
Second Genome, Inc., a leader in the development of novel medicines through innovative microbiome science, announced today that it has appointed Jim Sjoerdsma as executive vice president of human resources and Brian Dowd as senior vice president of finance.
“Jim and Brian bring broad experience and creative ideas to Second Genome’s leadership team as we continue to grow our microbiome profiling platform to tackle new challenges, as well as expand our pipeline programs,” said Glenn Nedwin, Chief Executive Officer and President of Second Genome. “I expect that they will greatly support our continued growth in the years ahead.”
Mr. Sjoerdsma brings more than 25 years of experience in human resources to his position, in which he will lead all recruitment, hiring, onboarding, training and organizational development of Second Genome employees. Prior to his current role, Sjoerdsma served in various roles in human resources for Genencor at all stages of its growth – from start-up to publicly traded to its acquisition by DuPoint BioSciences. While at Genencor, he developed a corporate culture that led to the company’s recognition as a “Great Place to Work” in four countries, including awards as the top company of its size by Fortune Magazine and the San Francisco Chronicle. Sjoerdsma earned his master’s degree in business administration from Nova Southeastern University and his bachelor’s degree in economics and business from Cornell College. Sjoerdsma holds an executive certificate in strategy and organization from Stanford University.
Mr. Dowd brings more than 25 years of financial and transactional experience to his position, in which he will oversee all financial operations and transactional activities for Second Genome. Mr. Dowd joins Second Genome from Johnson & Johnson, where he served as the vice president, controller of Alios BioPharma, which was acquired by Johnson & Johnson through Janssen Pharmaceuticals in November 2014. Before this, he served as the chief financial officer for Mondee Inc., a private technology solution provider, and previously held various leadership roles at Codexis, Inc., including interim chief financial officer and vice president, corporate controller, during its transition from a private company to a publicly traded company. Earlier in his career, he served in several senior financial roles with VeriFone Holdings, Inc., and other technology companies. Mr. Dowd began his career as an auditor at Deloitte. He earned his bachelor’s degree in business administration, accounting and finance from California Polytechnic University at San Louis Obispo.
About Second Genome
Second Genome’s mission is to transform lives with medicines developed through innovative microbiome science. Second Genome has built a novel platform for microbiome drug discovery. The company has established a pipeline of therapeutic products for the treatment of inflammation and metabolic diseases. Please visit www.secondgenome.com for more information.
Canale Communications Inc.